Jukka Westerbacka
Overview
Explore the profile of Jukka Westerbacka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
2458
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Nurmi J, Lindsberg P, Happola O, Klemetti E, Westerbacka J, Castren M
Acad Emerg Med
. 2011 Apr;
18(4):436-9.
PMID: 21496149
Objectives: The objective was to assess the feasibility of insulin infusion and subcutaneous insulin administered in the prehospital setting and their relative effect on hyperglycemia, a predictor of unfavorable outcome,...
22.
Lundbom J, Hakkarainen A, Soderlund S, Westerbacka J, Lundbom N, Taskinen M
NMR Biomed
. 2010 Sep;
24(3):238-45.
PMID: 20821410
Cross-talk between adipose tissue and liver is disturbed in the metabolic syndrome. Moreover, the relative fatty acid composition of adipose and liver fat is poorly characterized. Long-TE (1)H MRS can...
23.
Sevastianova K, Hakkarainen A, Kotronen A, Corner A, Arkkila P, Arola J, et al.
Radiology
. 2010 Jul;
256(2):466-73.
PMID: 20656836
Purpose: To determine if 3.0-T proton-decoupled phosphorus 31 ((31)P) magnetic resonance (MR) spectroscopy can be used to differentiate between stages of nonalcoholic fatty liver disease (NAFLD) by resolving the components...
24.
Westerbacka J, Kotronen A, Fielding B, Wahren J, Hodson L, Perttila J, et al.
Gastroenterology
. 2010 Jul;
139(6):1961-1971.e1.
PMID: 20600015
Background & Aims: Animal studies suggest that endocannabinoids could contribute to the development of nonalcoholic fatty liver disease (NAFLD). In addition, NAFLD has been shown to be associated with multiple...
25.
Lundbom J, Hakkarainen A, Fielding B, Soderlund S, Westerbacka J, Taskinen M, et al.
NMR Biomed
. 2010 Jan;
23(5):466-72.
PMID: 20099371
The aim of this study was to investigate the use of (1)H-MRS with various echo times to characterize subcutaneous human adipose tissue (SAT) triglyceride composition and to validate the findings...
26.
Kotronen A, Seppanen-Laakso T, Westerbacka J, Kiviluoto T, Arola J, Ruskeepaa A, et al.
Obesity (Silver Spring)
. 2009 Oct;
18(5):937-44.
PMID: 19798063
Ceramides may mediate saturated fat-induced insulin resistance, but there are no data comparing ceramide concentrations between human tissues. We therefore performed lipidomic analysis of human subcutaneous (SCfat) and intra-abdominal (IAfat)...
27.
Di Marzo V, Verrijken A, Hakkarainen A, Petrosino S, Mertens I, Lundbom N, et al.
Eur J Endocrinol
. 2009 Sep;
161(5):715-22.
PMID: 19745037
Objective: Endocannabinoids (ECs) control metabolism via cannabinoid receptors type 1 (CB1). Their plasma levels are elevated in overweight type 2 diabetes (T2D) and in obese patients, and decrease postprandially in...
28.
Aminoff A, Ledmyr H, Thulin P, Lundell K, Nunez L, Strandhagen E, et al.
J Lipid Res
. 2009 Jun;
51(1):103-11.
PMID: 19546343
Promoter polymorphisms in microsomal triglyceride transfer protein (MTTP) have been associated with decreased plasma lipids but an increased risk for ischemic heart disease (IHD), indicating that MTTP influences the susceptibility...
29.
Kotronen A, Yki-Jarvinen H, Aminoff A, Bergholm R, Pietilainen K, Westerbacka J, et al.
Eur J Endocrinol
. 2009 Feb;
160(4):593-602.
PMID: 19208777
Aims: We investigated whether polymorphisms in candidate genes involved in lipid metabolism and type 2 diabetes are related to liver fat content. Methods: Liver fat content was measured using proton...
30.
Hiukka A, Westerbacka J, Leinonen E, Watanabe H, Wiklund O, Hulten L, et al.
J Am Coll Cardiol
. 2008 Dec;
52(25):2190-7.
PMID: 19095138
Objectives: The aim of this substudy was to ascertain whether long-term treatment with fenofibrate reduces surrogate measures of atherosclerosis, biomarkers of inflammation, and endothelial activation in patients with type 2...